Sun Pharma Advanced Q1 FY27 Results: Revenue Rs 39 Cr, Net Loss Rs 20 Cr and Key Highlights
- August 11, 2026
- Posted by: Kunal Singla
- Category: News
Sun Pharma Advanced Q1 FY27 results declared August 10, 2026. Revenue Rs 39 Cr (+314.11% YoY). Net Loss Rs 20 Cr (+59.94% YoY). CMP Rs 207.38 (-2.73%).
Sun Pharma Advanced Q1 FY27 results were declared on August 10, 2026 on a consolidated basis. Revenue expanded +314.11% YoY to Rs 39 Cr from Rs 9.00 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs -36 Cr (+33.89% YoY). The company reported a net loss of Rs 20 Cr, providing the key financial picture for Sun Pharma Advanced Q1 FY27 results.
Click Here – Get Free Investment Predictions
Sun Pharma Advanced Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Sun Pharma Advanced Revenue | 39 | 9.00 | +314.11% |
| Operating Profit | -36 | -54 | +33.89% |
| Net Profit (PAT) | -20 | -51 | +59.94% |
| Reporting Basis | Consolidated | ||
Sun Pharma Advanced Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Sun Pharma Advanced Q1 FY27 results reflect strong fundamentals. Revenue momentum were evident with the top line reaching Rs 39 Cr for the April to June 2026 quarter.
Operating profit expanded +33.89% YoY. Net loss of Rs 20 Cr indicates recovery is still in progress. Investors tracking Sun Pharma Advanced Q1 FY27 results will note these as key FY27 milestones.
Key Business Factors in Sun Pharma Advanced Q1 FY27 Results
Revenue Expansion in Q1 FY27
Sun Pharma Advanced Q1 FY27 results show revenue expanding +314.11% YoY to Rs 39 Cr from Rs 9.00 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.
Operating Margin Performance
Operating profit in Sun Pharma Advanced Q1 FY27 results stood at Rs -36 Cr (+33.89% YoY). Better cost absorption and product mix improvement contributed to the operating performance.
Net Loss and Recovery Roadmap
Net loss of Rs 20 Cr in Sun Pharma Advanced Q1 FY27 results highlights near-term headwinds. Management is implementing cost optimisation and revenue scaling to return to profitability.
Dividend Details
No dividend was declared alongside Sun Pharma Advanced Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.
FY27 Outlook for Sun Pharma Advanced
Sun Pharma Advanced is positioned to sustain growth momentum through FY27, backed by order visibility, operational improvements, and sector tailwinds in the pharmaceuticals space. Investors tracking Sun Pharma Advanced Q1 FY27 results should consult a SEBI-registered financial advisor before making decisions.
Sun Pharma Advanced Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced live price and get daily stock recommendations.
Sun Pharma Advanced shares were trading lower at Rs 207.38 (-2.73%) on August 10, 2026, reflecting investor sentiment on Sun Pharma Advanced Q1 FY27 results and the near-term sector outlook. The CMP of Rs 207.38 on the results date reflects broader sentiment toward the pharmaceuticals space.
Key Risks for Sun Pharma Advanced
Sector-Specific Risks
USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.
Valuation and Earnings Risk
Valuation risk remains if quarterly growth fails to sustain over the next two to three quarters.
Operational and Financial Risk
Subsidiary-level underperformance could drag consolidated PAT lower in subsequent quarters.
Conclusion
Sun Pharma Advanced Q1 FY27 results highlight near-term challenges with revenue at Rs 39 Cr and a net loss of Rs 20 Cr on a Consolidated basis. Execution of the recovery plan will be the key catalyst to watch in coming quarters.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Sun Pharma Advanced Q1 FY27 Results
When were Sun Pharma Advanced Q1 FY27 results declared?
Ans. Sun Pharma Advanced Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Consolidated basis.
What was Sun Pharma Advanced revenue in Q1 FY27?
Ans. Revenue in Sun Pharma Advanced Q1 FY27 results was Rs 39 Cr, +314.11% YoY from Rs 9.00 Cr in Q1 FY26.
What was Sun Pharma Advanced PAT in Q1 FY27?
Ans. Net loss in Sun Pharma Advanced Q1 FY27 results was Rs 20 Cr (+59.94% YoY).
Did Sun Pharma Advanced declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Sun Pharma Advanced Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.
What is the FY27 outlook for Sun Pharma Advanced?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector demand and execution will be key monitorables.
How did Sun Pharma Advanced stock react to Q1 FY27 results?
Ans. Sun Pharma Advanced shares were lower at Rs 207.38 (-2.73%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.
